The Flare | Briefing #003
Focus Sector: Autoimmune Research & Clinical Access
MISSION: The Flare audits unpublished, shelved, withdrawn, and terminated clinical trial data in the autoimmune sector. We translate raw data into transparent briefings for patients, families, advocacy groups, and independent researchers.
Executive Summary
In February 2025, researchers published the first nationally standardized count of autoimmune disease in the U.S.: 15 million diagnosed Americans. That number is almost certainly low. At the same time, a key immune biomarker has been rising steadily for 25 years — and the specialist workforce responsible for diagnosing these conditions is heading toward a projected shortfall of over 100% by 2030. This briefing documents all three: the prevalence, the biomarker trend, and the access gap.
The New Baseline — 15 Million Diagnosed
For the first time, researchers used standardized methodology across six major U.S. health systems to count how many Americans have a diagnosed autoimmune disease. The result, published in the Journal of Clinical Investigation:
15 million Americans diagnosed with at least one autoimmune disease (4.6% of the U.S. population)
34% of those patients have more than one autoimmune disease
63% of all diagnosed patients are women
The Top 5 by Prevalence:
Rank | Condition | System Affected |
|---|---|---|
1 | Rheumatoid Arthritis | Joints / Systemic |
2 | Psoriasis | Skin |
3 | Type 1 Diabetes | Pancreas / Endocrine |
4 | Graves' Disease | Thyroid |
5 | Autoimmune Thyroiditis (Hashimoto's) | Thyroid |
Why 15 million is a floor, not a ceiling: The study only counted patients with at least two recorded diagnoses inside its six health systems. Anyone undiagnosed, misdiagnosed, or outside those networks is not in the number. Prior estimates aggregating 140-plus conditions place the total as high as 50 million — a range the NIH's own 2025 Strategic Plan acknowledges as plausible.
The Biomarker Signal — ANA Is Rising
Antinuclear antibody (ANA) is the primary blood test used to screen for autoimmune disease. Its prevalence in the U.S. population has increased significantly over 25 years:
Time Period | ANA Prevalence | Est. Americans Affected |
|---|---|---|
1988–1991 | 11.0% | ~22 million |
1999–2004 | 11.4% | ~27 million |
2011–2012 | 16.1% | ~41 million |
Among adolescents aged 12–19, the increase was nearly 300% over those three periods. The NIH has confirmed the trend is real but states the cause is not yet established.
A positive ANA does not mean someone has an autoimmune disease. It is a signal that warrants further evaluation — not a diagnosis.
The Diagnosis Gap — 4.5 Years
Getting a name for what is wrong takes a long time. Patient survey data from the Autoimmune Association puts the average at 4.5 years and four physicians before diagnosis. For lupus specifically, a published clinical cohort measured a 47-month median from first symptom to confirmed diagnosis.
The delay is structural. Autoimmune symptoms are nonspecific, intermittent, and spread across organ systems. A patient may see a gastroenterologist, a dermatologist, and a neurologist before anyone assembles the full picture.
The Access Problem — 68 Days to See a Specialist
Even when a primary care provider suspects an autoimmune condition, getting to a rheumatologist is not straightforward:
Metric | Data |
|---|---|
Average new-patient wait, rheumatology | 68 days (longest of 11 specialties surveyed) |
Reported waits in some systems | Up to 12 months |
Counties with no adult rheumatologist | Almost all rural counties |
Projected demand/supply gap by 2030 | ~102% |
The 2015 ACR Workforce Study projected that by 2030, demand for rheumatologists will exceed supply by approximately 102%. Nearly half of the current rheumatology workforce is expected to retire by then.
What you can do while you wait: Ask your primary care provider to order baseline bloodwork before your rheumatology appointment — an ANA panel, CBC, CMP, ESR, CRP, and thyroid function tests are all orderable in primary care. Arriving with that data shortens the diagnostic process.
The Clinical Intelligence Brief
Antinuclear Antibody (ANA). The standard first-line blood screen for systemic autoimmune disease. It detects antibodies targeting the cell nucleus. A positive result at a titer of 1:80 or higher — measured by indirect immunofluorescence on HEp-2 cells — is considered a significant signal when combined with symptoms. It is not a standalone diagnosis.
Verified Source Index
Abend AH et al. Journal of Clinical Investigation, Feb. 2025. PMC11827834
Miller FW et al. Current Opinion in Immunology, 2023. PMC9918670
Wincup C et al. Arthritis Research & Therapy, 2021. PMC7933718
Mannion ML et al. Arthritis & Rheumatology, 2024. DOI: 10.1002/art.42833
Miloslavsky EM et al. Seminars in Arthritis and Rheumatism, 2020. PMC7255118
Legal Disclaimer: The Flare is an independent investigative journalism outlet. We are not medical providers, clinical trial sites, or financial advisors. The information published in this briefing is for educational and journalistic purposes only and does not constitute medical advice. Always consult a qualified medical professional for health-related decisions. The Flare does not endorse any pharmaceutical product, therapeutic approach, or clinical trial sponsor.
